CORALVILLE, Iowa, April 05, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the Needham & Company’s 15th Annual Healthcare Conference being held in New York, NY, April 12 - 13, 2016.
Details of KemPharm's presentation are as follows:
Date: Tuesday, April 12, 2016
Time: 10:40 AM (ET)
Location: Westin NY Grand Central Hotel; New York, NY
The presentation will be webcast and available on the Investor Relations section of the Company's website at http://investors.kempharm.com/.
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 firstname.lastname@example.org email@example.com Media Contact: Jim Heins Cooney Waters Unlimited 212-886-2221 firstname.lastname@example.org